Bioventus (NYSE:BVS – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Canaccord Genuity Group in a report released on Monday,Benzinga reports. They presently have a $15.00 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback